Isolation of fluconazole-resistant strains of Candida species from human immunodeficiency virus (HIV)-infected patients after repeated or continuous courses of treatment has been reported with increasing frequency. During 1991-1992, MICs of fluconazole for 139 Candida albicans isolates from our institution were bimodally distributed: 102 strains were susceptible (MICs, sg/mL) and 37 were resistant (MICs, a8 Ag/mL). There was incomplete .crossresistance between fluconazole and ketoconazole or miconazole, and there was no cross-resistance between azoles and amphotericin B or flucytosine. Twenty of the 37 fluconazole-resistant strains were isolated from 17 HIV-negative patients, some with systemic infections, who had never been treated with azoles. There were no differences in characteristics or risk factors for those patients as compared with those for an equal number of HIV-negative patients from whom fluconazole-susceptible strains were isolated. Among patients with systemic infection, 6 (50%) of 12 with infection caused by fluconazole-resistant strains survived and 11 (69%) of 16 with infection caused by fluconazole-susceptible strains survived (P = .54). Survival was not found to be related to treatment regimen, but the number of patients was small. The emergence of fluconazole-resistant C. albicans among HIV-negative patients never exposed to azoles is of concern.
Infections due to Candida species have been increasing in frequency. According to the National Nosocomial Infections Surveillance System, Candida species organisms are now the fourth most common pathogens associated with nosocomial infections [1] . While administration of amphotericin B has been the standard therapy for such infections, fluconazole has been used successfully in treatment and prophylaxis for both human immunodeficiency virus (HIV)-infected [2] [3] [4] and HIV-negative patients [5] [6] [7] [8] [9] . In addition to its efficacy, it is also an attractive treatment alternative because it is easily administered, is well-tolerated, and lacks serious side effects [9] . Some Candida species such as Candida krusei and the related yeast Torulopsis glabrata, however, are intrinsically resistant to fluconazole [10, 11] , and the emergence of resistance during treatment of Candida albicans infections has recently been observed among HIV-infected patients [12] [13] [14] [15] [16] [17] [18] [19] In this study we report on the antifungal susceptibility of 139 strains of C. albicans isolated from patients at The Ohio State University Medical Center (Columbus, OH) during 1991 and 1992, and we review the records of 17 HIV-negative patients from whom fluconazole-resistant strains were isolated. For comparison, the records of 17 randomly selected HIV-negative patients from whom fluconazole-suscep-
Materials and Methods
During 1 99 1 -1 992, 139 strains of C. albicans isolated from 123 patients at The Ohio State University Medical Center were tested for susceptibility to antifungal agents. Indications for susceptibility testing included (1) isolation from blood, vascular catheters, or normally sterile body sites and fluids and (2) a request from the physician (regardless of site of recovery). Thirty-seven strains were fiuconazole-resistant; 20 of these were isolated from 17 of 100 HIV-negative patients.
Broth microdilution susceptibility tests were performed with use of the following antifungal agents: fluconazole (Roerig-Pfizer, Groton, CT), ketoconazole and miconazole (Janssen Pharmaceuticals, Piscataway, NJ ), flucytosine (Hoffmann-LaRoche, Nutley, NJ), and amphotericin B (E. R. Squibb & Sons, Princeton, NJ). All antifungal agents were supplied as standard reference powders with assayed potency. Stock solutions were prepared as follows: fluconazole and flucytosine were dissolved in sterile distilled water, ketoconazole was dissolved in 0.2N HC1, and miconazole and amphotericin B were dissolved in dimethyl sulfoxide.
Three media were used to prepare dilution series of the various antifungal agents for testing. Fluconazole was tested in HR medium (Oxoid, Basingstoke, Hampshire, England) buffered to pH 7.0 with 0.3M MOPS (4-morpholinepropanesulphonic acid). Ketoconazole, miconazole, and flucytosine were tested in buffered yeast nitrogen base (Difco, Detroit; pH, 7.0). Amphotericin B was tested in Antibiotic Medium 3 (Difco; pH, 7.0). Stock solutions of antifungal agents were diluted in assay medium to the desired concentrations. A Quick Spense II multichannel dispenser (Dynatech Laboratories, Chantilly, VA) was used to deliver 0.1 mL of the drug dilutions into sterile, 96-well, round-bottom plates (Dynatech Laboratories). A growth-control well and medium blank were included for each of the three media. Prepared plates were sealed in plastic bags in groups of five and frozen at -70°C until used.
Clinical isolates were subcultured to yeast extract malt agar plates and incubated for 24-48 hours at 30°C. Five to 10 isolated colonies were used to prepare a standardized inoculum in sterile distilled water [20] . Plates were inoculated with a Quick Spense inoculator (Dynatech Laboratories), and the final inocula were of -1-5 X 10 4 organisms/mL. Inoculated plates were incubated at 35°C in air for 48 hours. The 50% inhibitory concentration was defined as the lowest Ketoconazole MIC (log2)
concentration of drug that reduced turbidity by >50% (in comparison with the control well without the drug) [21] , as determined spectrophotometrically with use of an MR 600 Microplate Reader (Dynatech Laboratories) operating at 570 nm. Currently, there is no standardized method for performing susceptibility tests with antifungal agents, and there are no recommended breakpoints available for interpretation [22] . In this study, we chose fluconazole MIC breakpoints for distinguishing resistant organisms (MIC, ktg/mL) from susceptible organisms (MIC, p,g/mL). This choice was not based on any known correlation of MIC values and outcome but was an attempt to distinguish strains with relatively high MICs from those with relatively low MICs (figure 1). In addition, these breakpoints seemed reasonable on the basis of the fact that a mean peak fluconazole serum concentration of 6.72 ms/mL was observed after a single oral 400-mg dose was given to normal volunteers who had fasted (unpublished data, Pfizer).
In December 1992, after the completion of the present study, the National Committee for Clinical Laboratory Standards (NCCLS) proposed a standard method for broth dilu- 
Results
Frequency-distribution bar graphs of the MICs of the antifungal drugs for the 139 strains of C. albicans isolated during 1991-1992 are shown in figure 1. Fluconazole MICs were bimodally distributed: 102 strains were susceptible (MIC, Ag/mL) and 37 were resistant (MIC, >8 zg/mL). Scattergrams comparing pairs of azole MICs are shown in figure 2 . There was incomplete cross-susceptibility and crossresistance between fluconazole and ketoconazole or miconazole; ketoconazole and miconazole MICs were more related. Flucytosine and amphotericin B had no cross-resistance with any other drug tested (data not shown).
Patients' characteristics and risk factors are shown in tables 1-3. There was no clear pattern of differences between the 17 patients infected with fluconazole-resistant strains of C. albicans and the 17 infected with fluconazole-susceptible strains.
The relationship between survival and treatment of the C. albicans infections with amphotericin B, fluconazole (200-400 mg/d), or both is shown in table 4. The rate of survival among the patients with systemic infections caused by fluconazole-resistant strains was 6 (50%) of 12, and among the patients with systemic infections caused by fluconazolesusceptible strains it was 11 (69%) of 16 (P = .54). Outcome was not found to be related to drug choice or susceptibility in either group.
Discussion
The emergence of fluconazole-resistant C. albicans infections among HIV-infected patients has been attributed, at least in part, to repeated or continuous treatment with azoles in the face of profound immunosuppression [14, 16, 19] . Among HIV-negative patients with C. albicans infection, reported treatment failures have usually occurred while the patient was receiving therapy with fluconazole [24] [25] [26] . The emergence of in vitro resistance in a significant percentage of C. albicans isolates from azole-naive, HIV-negative patients (some of whom have invasive disease) is a potential new problem, the reasons for which are unclear.
Although other investigators have reported a correlation between in vitro susceptibility to fluconazole and the response to treatment of C. albicans infections among HIVinfected patients [12] [13] [14] [15] , we were unable to confirm this relationship with regard to HIV-negative patients. It is likely, however, that any relationship between these variables and outcome was overshadowed by the severity of the underlying diseases in a small population of patients.
There is little information available on cross-resistance among the azoles. Among our isolates there was incomplete cross-resistance between fluconazole and ketoconazole or miconazole, and there was no cross-resistance between azoles and amphotericin B or flucytosine.
Although two studies concluded that fluconazole is as efficacious as but less toxic than amphotericin B in the treatment of candidemia [8, 9] , our results indicate the need to be cautious when using fluconazole in the initial treatment of life-threatening candidal infections and underscore the need for a standardized method of antifungal susceptibility testing that provides valid results.
